Cargando…

Quantitation and pharmacokinetic modeling of therapeutic antibody quality attributes in human studies

A thorough understanding of drug metabolism and disposition can aid in the assessment of efficacy and safety. However, analytical methods used in pharmacokinetics (PK) studies of protein therapeutics are usually based on ELISA, and therefore can provide a limited perspective on the quality of the dr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Yinyin, Monine, Michael, Huang, Yu, Swann, Patrick, Nestorov, Ivan, Lyubarskaya, Yelena
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2016
Materias:	Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4968108/ https://www.ncbi.nlm.nih.gov/pubmed/27216574 http://dx.doi.org/10.1080/19420862.2016.1186322

Ejemplares similares

Assessing in vivo dynamics of multiple quality attributes from a therapeutic IgG4 monoclonal antibody circulating in cynomolgus monkey
por: Li, Yinyin, et al.
Publicado: (2016)

A pediatric quantitative systems pharmacology model of neurofilament trafficking in spinal muscular atrophy treated with the antisense oligonucleotide nusinersen
por: Paris, Alessio, et al.
Publicado: (2022)

Fc glycans of therapeutic antibodies as critical quality attributes
por: Reusch, Dietmar, et al.
Publicado: (2015)

Multi-attribute Raman spectroscopy (MARS) for monitoring product quality attributes in formulated monoclonal antibody therapeutics
por: Wei, Bingchuan, et al.
Publicado: (2021)

Population Pharmacokinetic Modelling of Recombinant Factor IX Fc Fusion Protein (rFIXFc) in Patients with Haemophilia B
por: Diao, Lei, et al.
Publicado: (2014)

An age‐dependent mathematical model of neurofilament trafficking in healthy conditions
por: Paris, Alessio, et al.
Publicado: (2022)

Pharmacokinetics and pharmacodynamics of peginterferon beta-1a in patients with relapsingremitting multiple sclerosis in the randomized ADVANCE study
por: Hu, Xiao, et al.
Publicado: (2015)

Modeling Pharmacokinetics and Pharmacodynamics of Therapeutic Antibodies: Progress, Challenges, and Future Directions
por: Tang, Yu, et al.
Publicado: (2021)

Establishment of a highly precise multi-attribute method for the characterization and quality control of therapeutic monoclonal antibodies
por: Tajiri-Tsukada, Michiko, et al.
Publicado: (2020)

Pharmacokinetic and Pharmacodynamic Considerations in the Design of Therapeutic Antibodies
por: Leipold, Douglas, et al.
Publicado: (2018)

Quantitation and modeling of post-translational modifications in a therapeutic monoclonal antibody from single- and multiple-dose monkey pharmacokinetic studies using mass spectrometry
por: Xu, Xiaobin, et al.
Publicado: (2019)

Population‐Based Pharmacokinetic and Exposure‐Efficacy Analyses of Peginterferon Beta‐1a in Patients With Relapsing Multiple Sclerosis
por: Hu, Xiao, et al.
Publicado: (2017)

Consistency of quality attributes for the glycosylated monoclonal antibody Humira® (adalimumab)
por: Tebbey, Paul W, et al.
Publicado: (2015)

Population pharmacokinetics and standard uptake value ratio of aducanumab, an amyloid plaque–removing agent, in patients with Alzheimer’s disease
por: Kandadi Muralidharan, Kumar, et al.
Publicado: (2021)

A Semi‐Mechanistic Population Pharmacokinetic Model of Nusinersen: An Antisense Oligonucleotide for the Treatment of Spinal Muscular Atrophy
por: Biliouris, Konstantinos, et al.
Publicado: (2018)

Pharmacokinetics, Pharmacodynamics, and Safety of Peginterferon Beta-Ia in Subjects with Normal or Impaired Renal Function
por: Hu, Xiao, et al.
Publicado: (2015)

Quantitative systems pharmacology model for Alzheimer’s disease to predict the effect of aducanumab on brain amyloid
por: Lin, Lin, et al.
Publicado: (2022)

Evaluation of the structural, physicochemical, and biological characteristics of SB4, a biosimilar of etanercept
por: Cho, Ick Hyun, et al.
Publicado: (2016)

COMPARE: Pharmacokinetic profiles of subcutaneous peginterferon beta‐1a and subcutaneous interferon beta‐1a over 2 weeks in healthy subjects
por: Hu, Xiao, et al.
Publicado: (2016)

Recent Advances in Translational Pharmacokinetics and Pharmacodynamics Prediction of Therapeutic Antibodies Using Modeling and Simulation
por: Haraya, Kenta, et al.
Publicado: (2022)

Clinically relevant dosing and pharmacokinetics of DNA-encoded antibody therapeutics in a sheep model
por: Hollevoet, Kevin, et al.
Publicado: (2022)

Application of Modelling and Simulation Approaches to Predict Pharmacokinetics of Therapeutic Monoclonal Antibodies in Pediatric Population
por: Lim, Andrew, et al.
Publicado: (2023)

Main Quality Attributes of Monoclonal Antibodies and Effect of Cell Culture Components
por: Torkashvand, Fatemeh, et al.
Publicado: (2017)

Phase II Dose Selection for Alpha Synuclein–Targeting Antibody Cinpanemab (BIIB054) Based on Target Protein Binding Levels in the Brain
por: Kuchimanchi, Mita, et al.
Publicado: (2020)

A competitive binding-mass spectrometry strategy for high-throughput evaluation of potential critical quality attributes of therapeutic monoclonal antibodies
por: Zhang, Zhengqi, et al.
Publicado: (2022)

Mass spectrometry-based multi-attribute method in protein therapeutics product quality monitoring and quality control
por: Yang, Feng, et al.
Publicado: (2023)

A human programmed death-ligand 1-expressing mouse tumor model for evaluating the therapeutic efficacy of anti-human PD-L1 antibodies
por: Huang, Anfei, et al.
Publicado: (2017)

Utility of physiologically based pharmacokinetic modeling to predict inter-antibody variability in monoclonal antibody pharmacokinetics in mice
por: Liu, Shufang, et al.
Publicado: (2023)

Physiologically-based pharmacokinetic model for pulmonary disposition of protein therapeutics in humans
por: Jagdale, Prabhas, et al.
Publicado: (2022)

Modeling and Simulation of Aggregation of Membrane Protein LAT with Molecular Variability in the Number of Binding Sites for Cytosolic Grb2-SOS1-Grb2
por: Nag, Ambarish, et al.
Publicado: (2012)

A system identification approach for developing model predictive controllers of antibody quality attributes in cell culture processes
por: Downey, Brandon, et al.
Publicado: (2017)

Quantitative mental state attributions in language understanding
por: Jara-Ettinger, Julian, et al.
Publicado: (2021)

Exploring the analytical power of the QTOF MS platform to assess monoclonal antibodies quality attributes
por: Gomes, Ricardo A., et al.
Publicado: (2019)

Assessment of chemical modifications of sites in the CDRs of recombinant antibodies: Susceptibility vs. functionality of critical quality attributes
por: Haberger, Markus, et al.
Publicado: (2014)

Translational Approach for Predicting Human Pharmacokinetics of Engineered Therapeutic Monoclonal Antibodies with Increased FcRn-Binding Mutations
por: Haraya, Kenta, et al.
Publicado: (2022)

Pharmacokinetics, immunogenicity and bioactivity of the therapeutic antibody catumaxomab intraperitoneally administered to cancer patients
por: Ruf, Peter, et al.
Publicado: (2010)

Pharmacokinetics of Monoclonal Antibodies
por: Ryman, Josiah T., et al.
Publicado: (2017)

Patient Satisfaction, Quality Attributes, and Organizational Characteristics: A Hierarchical Linear Model Approach
por: Otani, Koichiro, et al.
Publicado: (2019)

Physiologically‐based pharmacokinetic modeling of immunoglobulin and antibody coadministration in patients with primary human immunodeficiency
por: Salerno, Sara N., et al.
Publicado: (2022)

Glycoform-resolved pharmacokinetic studies in a rat model employing glycoengineered variants of a therapeutic monoclonal antibody
por: Falck, David, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_tenvf573fgcopap4lm30g5e0jn